Mechanism of Action: DK2¹⁰(EGFR)

  • Post published:July 30, 2025

Below, you’ll find a visual overview of DK210(EGFR)’s multi-functional mechanism, followed by a closer look at how each feature drives its unique anti-tumor profile.

The following figures provide a closer look at each component of the Diakines™ mechanism of action.

TARGETING
DK210(EGFR) is a tri-specific fusion protein that couples wild-type IL-2 with an IL-10 mutein with an EGFR directed scFv. This molecule is retained in the tumor microenvironment via accumulation at the tumor cell surface by binding EGFR (Figure 1).

Figure 1: Targeting to EGFR enables accumulation and retention in the tumor.

BALANCING
The molecule balances the inflammatory toxicity of IL-2 with IL-10’s anti-inflammatory function (Figure 2).

Figure 2: Coupling IL-10 with IL-2 blocks IL-2 induced toxic inflammation.

ACTIVATION
The combination of functions dissociates toxicity from potent broad-spectrum activation of the adaptive and innate anti-tumor immune responses (Figure 3).

Figure 3: Combining IL-2 with IL-10 permits IFNγ induction while enhancing Granzyme B and Perforin induction.

SYNERGY
The combination of all three effector functions enables enhanced anti-tumor function (Figure 4).

Figure 4: Targeting the tumor enhances the efficacy of the combined cytokines.